Howard Welgus Sells 635 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Posted by on Jun 19th, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) Director Howard Welgus sold 635 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $25.67, for a total value of $16,300.45. Following the completion of the transaction, the director directly owned 37,743 shares in the company, valued at approximately $968,862.81. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $26.21 on Friday. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -873.38 and a beta of 1.51. Arcutis Biotherapeutics, Inc. has a 52 week low of $13.06 and a 52 week high of $31.77. The company has a quick ratio of 2.46, a current ratio of 2.68 and a debt-to-equity ratio of 0.54. The firm has a 50 day moving average of $22.74 and a 200-day moving average of $25.12.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). The company had revenue of $105.40 million for the quarter, compared to analyst estimates of $103.67 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. On average, equities analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.15 earnings per share for the current year.

Institutional Trading of Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC lifted its stake in shares of Arcutis Biotherapeutics by 14.2% in the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock valued at $347,435,000 after buying an additional 1,486,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Arcutis Biotherapeutics by 1,228.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock worth $33,872,000 after acquiring an additional 1,078,546 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Arcutis Biotherapeutics during the fourth quarter worth about $26,136,000. State Street Corp raised its holdings in shares of Arcutis Biotherapeutics by 18.2% in the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after acquiring an additional 846,986 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 3rd quarter worth about $15,711,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ARQT shares. Wall Street Zen lowered shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen raised their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Mizuho decreased their target price on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcutis Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Read Our Latest Research Report on Arcutis Biotherapeutics

About Arcutis Biotherapeutics

(Get Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

Featured Stories

Insider Buying and Selling by Quarter for Arcutis Biotherapeutics (NASDAQ:ARQT)

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.